scholarly journals Association between post-diagnostic use of cholera vaccine and risk of death in prostate cancer patients

2018 ◽  
Vol 9 (1) ◽  
Author(s):  
Jianguang Ji ◽  
Jan Sundquist ◽  
Kristina Sundquist
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Cholera Vaccine ◽  
Risk Of Death ◽  
Diagnostic Use

Down-regulation of miR-219-5p increase the risk of cancer-related mortality in patients with prostate cancer

2021 ◽  
pp. postgradmedj-2021-139981
Author(s):  
Shimin Tang ◽  
Hao Jiang ◽  
Zhijun Cao ◽  
Qiang Zhou
Keyword(s):  
Prostate Cancer ◽  
Prediction Model ◽  
Cancer Patients ◽  
Cox Regression ◽  
Cox Model ◽  
Risk Of Death ◽  
Kaplan Meier ◽  
Risk Of Progression ◽  
Patient Prognosis ◽  
Risk Of Cancer

IntroductionProstate cancer is a common malignancy in men that is difficult to treat and carries a high risk of death. miR-219-5p is expressed in reduced amounts in many malignancies. However, the prognostic value of miR-219-5p for patients with prostate cancer remains unclear.MethodsWe retrospectively analysed data from 213 prostate cancer patients from 10 June 2012 to 9 May 2015. Overall survival was assessed by Kaplan-Meier analysis and Cox regression models. Besides, a prediction model was constructed, and calibration curves evaluated the model’s accuracy.ResultsOf the 213 patients, a total of 72 (33.8%) died and the median survival time was 60.0 months. We found by multifactorial analysis that miR-219-5p deficiency increased the risk of death by nearly fourfold (HR: 3.86, 95% CI): 2.01 to 7.44, p<0.001) and the risk of progression by twofold (HR: 2.79, 95% CI: 1.68 to 4.64, p<0.001). To quantify each covariate’s weight on prognosis, we screened variables by cox model to construct a predictive model. The Nomogram showed excellent accuracy in estimating death’s risk, with a corrected C-index of 0.778.ConclusionsmiR-219-5p can be used as a biomarker to predict death risk in prostate cancer patients. The mortality risk prediction model constructed based on miR-219-5p has good consistency and validity in assessing patient prognosis.

Immunohistochemical ETS-related gene detection in a Japanese prostate cancer cohort: Diagnostic use in Japanese prostate cancer patients

2011 ◽  
Vol 61 (7) ◽  
pp. 409-414 ◽  
Author(s):  
Bungo Furusato ◽  
Geert J.H.L. van Leenders ◽  
Jan Trapman ◽  
Takahiro Kimura ◽  
Shin Egawa ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Related Gene ◽  
Gene Detection ◽  
Diagnostic Use

Post-diagnostic use of beta-blockers and the risk of death in patients with prostate cancer

2014 ◽  
Vol 50 (16) ◽  
pp. 2838-2845 ◽  
Author(s):  
Jonathan Assayag ◽  
Michael N. Pollak ◽  
Laurent Azoulay
Keyword(s):  
Prostate Cancer ◽  
Beta Blockers ◽  
Risk Of Death ◽  
Diagnostic Use

scholarly journals Long-Term Competing Risk of Death In Prostate Cancer Patients After Prostatectomy

2020 ◽  
Vol 108 (3) ◽  
pp. e903
Author(s):  
N.G. Zaorsky ◽  
K. Stoltzfus ◽  
C. Lin ◽  
J. Liang ◽  
A.U. Kishan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Competing Risk ◽  
Risk Of Death

PSA failure and the risk of death in prostate cancer patients treated with radiotherapy

2004 ◽  
Vol 60 (4) ◽  
pp. 1040-1046 ◽  
Author(s):  
Winkle Kwan ◽  
Tom Pickles ◽  
Graeme Duncan ◽  
Mitchell Liu ◽  
Alexander Agranovich ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Risk Of Death ◽  
Psa Failure

scholarly journals Circulating vitamin D level and mortality in prostate cancer patients: a dose–response meta-analysis

2018 ◽  
Vol 7 (12) ◽  
pp. R294-R303 ◽  
Author(s):  
Zhen-yu Song ◽  
Qiuming Yao ◽  
Zhiyuan Zhuo ◽  
Zhe Ma ◽  
Gang Chen
Keyword(s):  
Prostate Cancer ◽  
Vitamin D ◽  
Cancer Patients ◽  
Dose Response ◽  
Protective Factor ◽  
Meta Analysis ◽  
Random Effect Model ◽  
Hydroxyvitamin D ◽  
Risk Of Death ◽  
25 Hydroxyvitamin D

Previous studies investigating the association of circulating 25-hydroxyvitamin D level with prognosis of prostate cancer yielded controversial results. We conducted a dose–response meta-analysis to elucidate the relationship. PubMed and EMBASE were searched for eligible studies up to July 15, 2018. We performed a dose–response meta-analysis using random-effect model to calculate the summary hazard ratio (HR) and 95% CI of mortality in patients with prostate cancer. Seven eligible cohort studies with 7808 participants were included. The results indicated that higher vitamin D level could reduce the risk of death among prostate cancer patients. The summary HR of prostate cancer-specific mortality correlated with an increment of every 20 nmol/L in circulating vitamin D level was 0.91, with 95% CI 0.87–0.97, P = 0.002. The HR for all-cause mortality with the increase of 20 nmol/L vitamin D was 0.91 (95% CI: 0.84–0.98, P = 0.01). Sensitivity analysis suggested the pooled HRs were stable and not obviously changed by any single study. No evidence of publications bias was observed. This meta-analysis suggested that higher 25-hydroxyvitamin D level was associated with a reduction of mortality in prostate cancer patients and vitamin D is an important protective factor in the progression and prognosis of prostate cancer.

scholarly journals Prostatectomy Versus Observation for Localized Prostate Cancer: A Meta-Analysis

2019 ◽  
pp. 145749691988396
Author(s):  
Xiaojin Luo ◽  
Meilian Yi ◽  
Qun Hu ◽  
Weihua Yin
Keyword(s):  
Prostate Cancer ◽  
Erectile Dysfunction ◽  
Confidence Interval ◽  
Disease Progression ◽  
Cancer Patients ◽  
Risk Ratio ◽  
Localized Prostate Cancer ◽  
Urinary Function ◽  
Cancer Symptoms ◽  
Risk Of Death

Background and Aims: Controversy exists regarding whether prostatectomy benefits localized prostate cancer patients; the aim of our study was to evaluate the role of prostatectomy in localized prostate cancer patients. Materials and Methods: A systematic search was conducted using PubMed and Web of Science through March 22, 2019, according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines to identify randomized studies reporting on prostatectomy for localized prostate cancer patients. Results: Of a total of 1827 studies, six were considered for evidence synthesis. A total of 2524 patients in 3 studies were included for survival analysis, where 1256 patients received prostatectomy and 1268 patients received no treatment but were regularly followed up. Three other studies were included for adverse effects analysis. Prostatectomy displayed a significantly decreased risk of death of 9% compared with that of observation for patients with localized prostate cancer (risk ratio = 0.91; 95% confidence interval, 0.85–0.97; p = 0.007). Pooled data indicated that prostatectomy reduced the risk of disease progression by 43% (risk ratio = 0.57; 95% confidence interval, 0.47–0.70; p < 0.00001). Anxiety, depressed mood, well-being, and sense of meaningfulness for patients were not different between the prostatectomy and observation groups. However, prostatectomy increased the risk of erectile dysfunction by 2.10-fold (risk ratio = 2.10; 95% confidence interval, 1.36–3.26; p = 0.0009) and the risk of urinary function problems by 2.02-fold (risk ratio = 2.02; 95% confidence interval, 1.15–3.54; p = 0.01). Conclusion: Prostatectomy prolonged survival and deferred disease progression compared to observation for patients with localized prostate cancer. Symptoms between the two groups were not significantly different except for erectile and urinary function. Patients should decide on prostatectomy after balancing the survival benefit and risk of erectile dysfunction.

Impact of androgen deprivation therapy on mortality of prostate cancer patients with COVID-19: A propensity score-based analysis.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 5067-5067
Author(s):  
Mateus Bringel Oliveira Duarte ◽  
Frederico Leal ◽  
Juliana Luz Passos Argenton ◽  
Jose Barreto Campello Carvalheira
Keyword(s):  
Prostate Cancer ◽  
Propensity Score ◽  
Cancer Patients ◽  
Androgen Deprivation Therapy ◽  
Protective Factor ◽  
Androgen Deprivation ◽  
Average Treatment Effect ◽  
Outcome Analysis ◽  
Risk Of Death ◽  
Double Robust

5067 Background: Previous studies suggested that androgen deprivation therapy (ADT) may reduce severe acute respiratory syndrome coronavirus 2 (SARS-COV2) infectivity. However, it is unknown whether there is an association between ADT and a higher survival in prostate cancer patients with COVID-19. Methods: We performed a retrospective analysis of prostate cancer (PC) patients hospitalized to treat COVID-19 in Brazil’s public health system. We compared patients with the active use of ADT versus those with non-active ADT, past use. We constructed propensity score models of patients in active versus non-active use of ADT. All variables were used to derive propensity score estimation, and for the outcome analysis we performed a multivariate backward elimination process to select variables to add to the propensity score model. Results: We analyzed 109 PC patients with COVID-19 that presented past or current use of ADT. In total, 52.8% of our patients were less than 75 years old, 44.0% (48/109) were in active ADT, and most were using a GnRH analog (73%, 35/48). Also, 63.3% of our cohort died from COVID-19. ADT active use were protective factor in our logistic regression model (OR 0.28, 95% CI 0.12–0.66, P = 0.0036). We noticed a significant imbalance in the propensity score of patients in active and those in non-active ADT. Then, when we performed a propensity score-based inverse weight double robust estimation model, we observed that ADT remained statistically associated with improved overall survival (average treatment effect [ATE] -0.26, 95% CI -0.45 to -0.08, P = 0.0058). Conclusions: The active use of ADT was associated with a reduced risk of death in patients with COVID-19.

Sign in / Sign up

Export Citation Format

Share Document